foxo4-dri senolytic peptide human trials regulates endothelial cell senescence via the P53 signaling pathway Buy FOXO4-DRI 10mg | Third-Party
Buy FOXO4 DRI 10mg Third Party Tested BioEdge Peptides The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv FOX04 DRI Apollo Peptide Sciences
Pay in 4 interest-free payments of $6.02 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17



